We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Brain Stem Cells Produce Insulin

By Biotechdaily staff writers
Posted on 13 May 2005
Researchers have been able to coax stem cells from the brain to mature into cells that can produce insulin and release it when sugar is added to the environment. More...
This feat could lead to new ways of transplanting insulin-producing cells into diabetics.

Because embryonic stem cells are difficult to work with in a laboratory and most existing human embryonic stem cells lines are contaminated and cannot be transplanted into humans, an alternative was sought by Seung Kim, M.D., Ph.D., assisstant professor of developmental biology at the Stanford University School of Medicine (Palo Alto, CA).

Dr. Kim thought that human neural stem cells might work. "When you look at islet cells you realize that they resemble neurons,” he noted. Like neurons, islet cells respond to external signals by changing their electrical properties and releasing packages of proteins. In the case of islets, that protein is insulin. In fact, the cells that produce insulin and regulate sugar in fruit flies are neurons.

Working with the cells in a lab dish, Dr. Kim and postdoctoral fellow Yuichi Hori, M.D., Ph.D., added a cocktail of chemicals in a sequence they knew might prod the stem cells to mature into insulin-producing cells. The result was a dish full of cells that could produce insulin and release it in response to sugar being added. These cells did not perfectly mimic human islet cells. They made some, but not all, proteins normally made by islet cells and they continued to make some proteins found in neurons.

Dr. Kim then transplanted the cells into a cavity in the kidneys of mice. When the blood sugar went up in these mice, the cells released insulin. After four weeks, the cells were still alive and producing insulin. Although the amount of insulin produced was not enough to treat diabetes, the work is a first step toward that eventual goal. Dr. Kim is the lead author of a paper describing the project, published in the April 26, 2005, issue of PLoS Medicine.


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automatic CLIA Analyzer
Shine i6000
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.